If they did "cure" HepC (let's not mention the drop out rate of 40% which was a massive problem but downplayed), why after 10 years, is not being worked on or purchased, or on the shelf at a pharmacy?
The issue we have (us downies) and professor laver and his colleagues, is Bit overstates the science. HepC and HIC massively overhyped and we say it didn't meet its end points. Can't argue against it for HepC. Decade later and it's dead in the water. No further testing, no deal.
The fact that they engaged C14 proves that there is no interest from BP. C14 are being paid to find a buyer. Won't pay for C14 if there was genie interest .
The "proof" will be here soon. If C14 can't find a buyer or a buyer offers a disappointing low ball sum (punters are expecting 30 billion deals after all), then it's all over red rover. Maybe us downies will be wrong on this one. But with then patent clocking ticking, I don't the "interesting" tech is worth much.
as for Becker's "interest" comment..
i have to say the engagement of C14 has cured my bit fomo (what if I'm wrong, I'd miss out on next csl lol!).
Despite saying they've discussing with BP for 15 years and promising deals with nothing to show for it! Add on top of that the directors making $$& flogging their shares.
Like all good ponzis, they hooked me in. Glad, to be cured! Haha
stock down 99% against the Asx200 this year. Winning !!!
BIT Price at posting:
1.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)